UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL								
OMB Number:	3235-0287							
Estimated average b	ourden							
hours par response	0.5							

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)														
1. Name and Address of Reporting Person COLDBERG DAVID C (Last) (First) (Middle) C/O ENZO BIOCHEM INC, 527 MADISON AVE				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner				
					3. Date of Earliest Transaction (Month/Day/Year) 03/14/2016						X(X_Officer (give title below) Other (specify below) VP CorpDev IGM Enz Clin Labs				
NIEW V	ODE NIV	(Street)		4. If A	men	dment, Da	ite O	riginal Filed(Month/D	Day/Year)	_X_ For	m filed by O	ne Reporting Po	Filing(Check A erson eporting Person	applicable Line)	
(Cit	ORK, NY	(State)	(Zip)				Tab	ole I - Non-D	erivat	ive Securities	Acquired, D	isposed o	f, or Benefi	cially Owned	i	
1.Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Ye		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transaction		(A) o	curities Acquir r Disposed of (: 3, 4 and 5)	ired 5. Amount of Sec		curities Beneficially		Ownership of Form:	Beneficial Ownership			
		l	T	(e.g.,		s, calls, wa	ırraı	in this a curred, Dis	forn ently posed	ho respond to n are not req valid OMB of of, or Benefic rtible securition	uired to rescontrol nuncially Owned	spond ur nber.	nless the f	orm display	/s	474 (9-02)
	2. Conversion or Exercise Price of Derivative Security	rsion Date (Month/Day/Year) Exection of tive	3A. Deemed Execution Date, if any (Month/Day/Year)	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	Ownershi Form of Derivative Security: Direct (D or Indirec	(Instr. 4)	
				Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Stock										03/13/2021	Common	18,000	\$ 0			

D 4 0 V /	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
GOLDBERG DAVID C C/O ENZO BIOCHEM INC 527 MADISON AVE NEW YORK, NY 10022			VP CorpDev IGM Enz Clin Labs				

Signatures

/s/ David C. Goldberg	03/16/2016
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Reporting Person was granted 18,000 stock options. The options have a five-year term and shall vest in three equal annual tranches, begininning March 15, 2017.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.